Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer

被引：1
|
作者：
Barnett, I. [1 ]
Alvarez-Secord, A. [2 ]
Cohn, D. [3 ]
Leath, C. [1 ]
Peterson, B. [2 ]
Myers, E. [2 ]
Havrilesky, L. [2 ]
机构：
[1] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [33] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [34] Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
    Lai, Shih Ping
    Wang, Shyh-Yau
    Chan, Agnes L. F.
    Leung, John Hang
    Yip, Hei-Tung
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (04) : 541 - 549
  • [35] Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States
    Penn, Courtney A.
    Wong, Melissa S.
    Walsh, Christine S.
    [J]. JAMA NETWORK OPEN, 2020, 3 (12)
  • [36] Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer
    Jayson, Gordon
    [J]. ANGIOGENESIS, 2014, 17 (03) : 727 - 727
  • [37] Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
    Hashemi-Meshkini, Amir
    Keshavarz, Khosro
    Gharibnaseri, Zahra
    Kheirandish, Mehrnaz
    Kebriaeezadeh, Abbas
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (03) : 472 - 478
  • [38] COST-EFFECTIVENESS OF PROPHYLAXIS TREATMENT STRATEGIES FOR FEBRILE NEUTROPENIA IN RECURRENT OVARIAN CANCER PATIENTS
    Fust, K.
    Li, X.
    Maschio, M.
    Barron, R.
    Weinstein, M. C.
    Parthan, A.
    Walli-Attaei, M.
    Chandler, D. B.
    Lyman, G. H.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A140 - A140
  • [39] Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer
    Fust, Kelly
    Li, Xiaoyan
    Maschio, Michael
    Barron, Richard
    Weinstein, Milton C.
    Parthan, Anju
    Walli-Attaei, Marjan
    Chandler, David B.
    Lyman, Gary H.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 446 - 453
  • [40] Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer
    Huang, Chen-Yu
    Chang, Chia-Ming
    Wang, Peng-Hui
    [J]. TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2020, 59 (03): : 351 - 352
12345